Select Page

APC-2000—Albuterol DPI

If approved, the APC-2000 will be a Taper Dry Powder Inhalation (DPI) short-acting β2-adrenergic receptor agonist for the treatment of bronchospasms. For this product, Adamis is using albuterol (salbutamol) and combining it with a DPI propellant to relieve the symptoms of asthma.

Potential Indication: Bronchospasm

Bronchospasm is a narrowing of the airway caused by inflammation or irritation. During a bronchospasm, breathing becomes more difficult because the airways get smaller. This condition is often associated with asthma and can appear as a feature of chronic bronchitis and anaphylaxis.

Asthma is a chronic lung disease that inflames and narrows the airways. Asthma causes recurring periods of wheezing, chest tightness, shortness of breath, and coughing. Asthma affects people of all ages, but it most often starts during childhood. In the United States, more than 25 million people are known to have asthma and about 7 million of these people are children.

About the Taper DPI Technology Platform

As part of the acquisition agreement with 3M, Adamis has obtained worldwide rights to this Taper DPI platform technology in all indications in the dry powder inhalation field. The unique design uses proprietary 3M technology to store the active pharmaceutical ingredient (API) on a microstructured carrier tape. 3M will supply the drug delivery tape to Adamis under a separate supply agreement. In the future, Adamis intends to pursue other follow-on products using the Taper DPI patented technology platform with other formulations.